NEW YORK (GenomeWeb News) – GeneGo will use a grant totaling nearly $300,000 from the National Institute of General Medical Sciences to develop new data management software for use in pharmacogenomics research, the company said today.
The Small Business Innovation Research grant will fund development of a database and systems biology tool kit for studying mutations and sequence heterogeneity in human genes and their controlling regions, and for use in studying sequence variations involved in disease susceptibility and drug response.
The database will include information on SNPs, splice variants, translocations, CNVs, and other sequence alterations and transcription or translation of human, rat, or mouse proteins. It will include a knowledge base of literature-reported associations between human and rodent sequence information and proteomic data. The company plans to integrate the new tools the company develops into its Metadiscovery platform.
The grant period will last from July 2009 to June 2011, and will include three payments of $124,000; $25,000; and $148,000.
Richard Brennan, director of toxicology at GeneGo and PI on the grant, said in a statement that genome-wide association studies have generated "vast amounts of data on genetic factors contributing to disease, susceptibility and variability in the pharmacological and toxicological effects of drugs. What is lacking are powerful tools for researchers to be able to link these sequence variations to the specific mechanisms and biological pathways driving idiosyncratic outcomes."
Brennan said that the product the company is developing "will smooth the progress of personalized medicine by facilitating the application of personal genetic profiling to identify optimal therapeutic strategies."
"It allows us to develop novel tools and databases to help our customers mine important content from the literature, analyze their data and test their hypotheses," Julie Bryant, GeneGo's VP of business development, said in a statement.